Lutetium (Lu177-Octereotate) Therapy

Home Services Treatment Lutetium (Lu177-Octereotate) Therapy
Also referred to as targeted radionuclide therapy or (PRRT) Peptide Receptor Radionuclide therapy. It is usually the course of treatment suggested for patients suffering from neuroendocrine or carcinoid tumors. Octreotate and somatostatin are considered chemically related, as they both act as an agent that distributes Lu177 where it discharges sufficient amounts of beta radiation to destroy target active cells.

The kidneys and bone marrow reserves may be affected by radiation, though the radiation emitted to surrounding inactive cells is kept at minimum levels. Therefore, white blood cells and platelets reserves will be monitored twice a month through a CBC test twice a month, in addition to an amino-acid infusion to be administered with the treatment to reduce the radiation’s effect on the kidneys.

Before initiating the treatment, the following tests should be provided:
  • Either an MRI/CT scan report or a Ga68/CT, In-111 report
  • Recent CBC and KFT tests
  • A list of current medications should be provided as to avoid contradiction, for instance long acting somatostatin analogues should be withheld for 4 weeks